No Data
No Data
Addex Therapeutics Says Partner J&J Innovative Medicine Discontinues Development of ADX71149 to Treat Epilepsy; Addex Shares Fall Pre-Bell
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Express News | Addex Therapeutics - Janssen Informed Co It Discontinued Development of Adx71149 (Jnj-40411813) in Epilepsy
J&J Ends Work on Addex Epilepsy Drug Candidate ADX71149: Report
Addex Therapeutics Unveils Breakthrough Cough Treatment
Addex Presents Positive Results From GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
No Data